Fenofibrate for Cardiovascular Disease Prevention in Metabolic Syndrome and Type 2 Diabetes Mellitus

Clinical guidelines highlight the importance of managing atherogenic mixed dyslipidemia to reduce the risk of premature cardiovascular disease in type 2 diabetes mellitus and metabolic syndrome. The lipid-modifying activity of fenofibrate, as demonstrated in clinical studies, indicates its effective...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2008-12, Vol.102 (12), p.28L-33L
Main Author: Steiner, George, MD
Format: Article
Language:English
Subjects:
Atherosclerosis - prevention & control
Cardiology
Cardiovascular
Cardiovascular disease
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Disease Progression
Drug therapy
Fenofibrate - therapeutic use
Humans
Hypolipidemic Agents - therapeutic use
Metabolic syndrome
Metabolic Syndrome - complications
Metabolic Syndrome - drug therapy
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical guidelines highlight the importance of managing atherogenic mixed dyslipidemia to reduce the risk of premature cardiovascular disease in type 2 diabetes mellitus and metabolic syndrome. The lipid-modifying activity of fenofibrate, as demonstrated in clinical studies, indicates its effectiveness in treating dyslipidemia characteristic of these conditions. Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor–α. In patients with type 2 diabetes, fenofibrate is effective in reducing the progression of coronary artery disease, as demonstrated by the Diabetes Atherosclerosis Intervention Study (DAIS). In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, the primary end point (major coronary events) was not significantly reduced by fenofibrate treatment. However, other findings from this study suggest that fenofibrate reduces cardiovascular risk. Both DAIS and the FIELD study also indicate that fenofibrate may offer additional vascular benefits, specifically affecting the progression of diabetes-related microvascular disease.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2008.09.072